Abeona Therapeutics Inc (NASDAQ: ABEO) recently updated its phase 3 VITAL study to its shareholders and prospective investors. The company announced that it had attained its planned enlistment of participants for the study. Abeona intends to develop the compound to investigate the effectiveness of the company’s latest alternative to treating recessive dystrophic epidermolysis bullosa.
The E -101 is an alternative for the treatment of the disease
Abeona developed the EB-101 compound that acts as an alternative treatment method to the illness, thus creating VITAL to investigate the treatment’s side effects. Individuals affected with Recessive Dystrophic Epidermolysis Bullosa possess a defect in the COL7A1 genes that makes it impossible for one to manufacture type VII collagen in the body. The collagen assists in anchoring the skin’s dermal and epidermal membranes.
Abeona is presently evaluating the compound by developing VIITAL to confirm the side effects of the therapy on patients. The company created the compound to assist cell therapy in altering the COL7A1 genes; if VITAL detects little to no side effects, the compound will be the first approved therapy. Abeona’s research led to an unpredictable clinical trial that enlisted a minimum of 10 participants in the country.
The compound’s therapy entails conveying genes to transmit the necessary genes into an individual’s skin cells. The trained physicians will then transplant the harvested genes back to the individual’s skin following a few adjustments. First, VITAL evaluates the compound’s ability to allow standard forms of type VII collagen and fasten the wound’s healing.
Abeona develops alternative cell and gene therapies to treat severe infection
The company is among the leading companies in the country that focuses on creating alternative gene and cell therapies for severe illnesses. Abeona possesses various clinical programs such as EB-101, ABO -101, and ABO-102. In addition, the company’s portfolio possesses various award-winning therapies for various illnesses that do not have adequate treatment methods.
Abeona’s employment team is skilled with the knowledge to create EB-101, which is the cause of the VITAL study in phase 3. As a result, the company anticipates that the compound will be available for commercial purposes.
